O USO DA CAFEÍNA NA TERAPIA NUTRICIONAL DE PACIENTE COM DEPRESSÃO

Rute Salgues Gueiros dos Anjos; Mariana Otaviano Pereira C. de Albuquerque

doi:10.47820/recima21.v4i1.2584

Autores

Rute Salgues Gueiros dos Anjos https://orcid.org/0000-0003-3353-0764
Mariana Otaviano Pereira C. de Albuquerque

DOI:

https://doi.org/10.47820/recima21.v4i1.2584

Palavras-chave:

Antidepressivo, café, depressão, nootrópicos, terapia nutricional

Resumo

Café e chá são as bebidas mais consumidas no mundo depois da água, variando o padrão de consumo diante a cultura de cada país. Estudos demostram o uso da cafeína em pacientes adultos com depressão relacionada a sua genética e ao uso de fármacos. Esta revisão teve como objetivo avaliar o uso da cafeína na terapia nutricional de pacientes com depressão, caracterizar a influência e suas respostas metabólicas além de abordar estratégias nutricionais para melhora do quadro clínico na depressão. Tendo em vista que o número de casos da depressão cresce a cada dia, torna-se um problema na saúde pública relevante para a nutrição. Estudos abordam que a ingestão de alguns alimentos pode contribuir com a diminuição dos sintomas da depressão e proteção da função neuronal, além disso, fatores ambientais podem interferir trazendo prejuízos a saúde. Esta revisão abordou uma bibliografia que incluam artigos científicos e teses relacionados a depressão, cafeína, doenças neurológicas, citocromo p450 e metabolização fármaco-nutriente. Eles foram selecionados de acordo com critérios de inclusão e exclusão, utilizados bancos de dados com relevância científica, Pubmed, Scielo, publicados nos idiomas inglês, português e espanhol, por meio dos descritores em Ciência a Saúde (DeCS): antidepressivo, café, depressão, nootrópicos e terapia nutricional. Com essa revisão, foi verificado quais os benefícios e malefícios do consumo de alimentos que apresentam teores de cafeína, juntamente com a terapia medicamentosa de pacientes com depressão e sua influência na melhora cognitiva e neuroproteção, na prevenção de doenças neurodegenerativas e no bem-estar destes indivíduos.

Downloads

Não há dados estatísticos.

Biografia do Autor

Rute Salgues Gueiros dos Anjos

Bióloga, Mestre e Doutora em Ciências Biológicas pela Universidade Federal de Pernambuco; Doutora em Farmacogenômica pela Universidade Federal Rural de Pernambuco; Graduada pelo curso de Nutrição da UNINASSAU Pernambuco.

Mariana Otaviano Pereira C. de Albuquerque

Concluinte do curso de nutrição - UNINASSAU

Referências

Chang D, Song D, Zhang J, Shang Y, Ge Q, Wang Z. Caffeine Caused a Widespread Increase of Resting Brain Entropy. Scientific Reports. 2018; 8(1).

Santos C, Costa J, Santos J, Vaz-Carneiro A, Lunet N. Caffeine intake and dementia: a systematic review and meta-analysis. Journal of Alzheimer's Disease:JAD. 2010; 20 (Supplement 1):S187-204.

Ding M, Bhupathiraju SN, Satija A, Van Dam RM, Hu FB. Long-term coffee consumption and cardiovascular disease risk: a systematic review and a doseresponse meta-analysis of prospective cohort studies. Circulation. 2014; 129:643-59.

Ding M, Bhupathiraju SN, Chen M, van Dam RM, Hu FB. Caffeinated and decaffeinated coffee consumption and risk of type 2 diabetes: a systematic review and a dose-response meta-analysis. Diabetes care. 2014; 37:569-586.

Ross GW, et al. Association of coffee and caffeine intake with risk of Parkinson's disease. never. 2000; 283:2674-2679.

Freedman ND, Park Y, Abnet CC, Hollenbeck AR, Sinha R. Association of coffee consumption with total and cause-specific mortality. The New English Journal of medicine. 2012; 366:1891-1904.

Ding M, et al. Association of coffee consumption with total and cause-specific mortality in 3 large prospective cohorts. Circulation. 2015; 132:2305–2315.

Loftfield E, et al. Association of coffee consumption with general and cause-specific mortality in a large prospective cohort study in the USA. American Journal of Epidemiology. 2015; 182:1010–1022.

Cornelis MC, El-Sohemy A, Kabagambe EK, Campos H. Coffee, CYP1A2 genotype and risk of myocardial infarction. never. 2006; 295:1135-1141.

Feng L, Gwee X, Kua EH, Ng TP. Cognitive function and tea consumption in the Chinese elderly community in Singapore. Journal of Nutrition, Health and Aging. 2010; 14:433-438.

Araújo LF, et al. Association of coffee consumption with MRI markers and cognitive function: a population-based study. Journal of Alzheimer's Disease: JAD. 2016; 53:451-461.

Araújo LF, Giatti L, Reis RC, Goulart AC, Schmidt MI, Duncan BB, Ikram MA, Barreto SM. Inconsistency of Association between Coffee Consumption and Cognitive Function in Adults and Elderly in a Cross-Sectional Study (ELSA-Brasil). Nutrients. 2015 Nov 19;7(11):9590-601

McMahon G, Taylor AE, Davey Smith G, Munafò MR (2014) Phenotype Refinement Strengthens the Association of AHR and CYP1A1 Genotype with Caffeine Consumption. PLoS ONE 9(7): e103448.

Josse AR, Da Costa LA, Campos H, El-Sohemy A. Associations between polymorphisms in the AHR and CYP1A1-CYP1A2 gene regions and habitual caffeine consumption. The American Journal of Clinical Nutrition. 2012; 96:665-671.

Cornelis MC, et al. The genome-wide association study of caffeine metabolites provides new insights into caffeine metabolism and dietary caffeine consumption behavior. Human molecular genetics. 2016; 25:5472-5482.

Grosso G, Micek A, Castellano S, Pajak A, Galvano F. Coffee, tea, caffeine and risk of depression: A systematic review and dose-response meta-analysis of observational studies. Mol Nutr Food Res. 2016 Jan; 60(1):223-34.

Guengerich FP, Waterman MR, Egli M. Recent structural insights into cytochrome P450 function. Trends Pharmacol Sci 2016; 7(8):625-40.

Chuang, Yu-Hsuan, et al. "Gene-environment interaction in Parkinson's disease: coffee, ADORA2A, and CYP1A2." Neuroepidemiology 47.3-4 (2016): 192-200.

Hill-Burns, Erin M., et al. "An attempt to replicate interaction between coffee and CYP1A2 gene in connection to Parkinson’s disease." European journal of neurology: the official journal of the European Federation of Neurological Societies 18.9 (2011): 107.

Jee HJ, Lee SG, Bormate KJ, Jung YS. Effect of Caffeine Consumption on the Risk for Neurological and Psychiatric Disorders: Sex Differences in Human. Nutrients. 2020 Oct 9;12(10):3080.

Strafella C, Caputo V, Galota MR, Zampatti S, Marella G, Mauriello S, et al. Aplicação da Medicina de Precisão em Doenças Neurodegenerativas. Frente. Neural. 2018; 9:701.

Scalabrino G. Vitamin-regulated cytokines and growth factors in the CNS and elsewhere. J Neurochem. 2009 Dec;111(6):1309-26.

MOURA, Ribeiro M, Felix G. Interação fármaco-nutriente: uma revisão. Revista de Nutrição. 2002, v. 15, n. 2 Acessado 3 dezembro 2022, pp. 223-238.

Patel M, Taskar KS, Zamek- Gliszczynski MJ. Importance of hepatic transporters in clinical disposition of drugs and their metabolites. J Clin Pharmacol 56(Suppl 7):S23–S39, 2016.

Ortega MA, Fraile-Martínez Ó, García-Montero C, Alvarez-Mon MA, Lahera G, Monserrat J, et al. Biological Role of Nutrients, Food and Dietary Patterns in the Prevention and Clinical Management of Major Depressive Disorder. Nutrients. 2022 Jul 28;14(15):3099.

MAHAN LK, ESCOTT-STUMP, S RAYMOND, J.L Krause: Alimentos, Nutrição e Dietoterapia. 13ª ed. Rio de Janeiro: Elsevier, 2013. 1228 p.

Tavares, Cristiane e Sakata, Rioko K. Cafeína para o tratamento de dor. Revista Brasileira de Anestesiologia. 2012 v. 62, n. 3 pp. 394-401.

CAMPOS C. Alimentos com cafeína. In: STEIN, Kelly. 2011. Disponível em: Acesso 01 mai. 2017CAMPOS, apud STEIN, 2011

Vasconcelos S, Silva M, Goulart M. Pró-antioxidantes de baixo peso molecular oriundos da dieta: estrutura e função. 2006: 31(3) 95-118

Perera V, Gross AS, Xu H, McLachlan AJ. Farmacocinética da cafeína no plasma e na saliva e a influência da abstinência de cafeína nas métricas do CYP1A2. J Pharm Pharmacol. 2011;63(9):1161-8.

Malik R, Sangwan A, Saihgal R, Jindal DP, Piplani P. Towards better brain management: nootropics. Curr Med Chem. 2007;14(2):123-31.

Malík M, Tlustoš P. Nootropics as Cognitive Enhancers: Types, Dosage and Side Effects of Smart Drugs. 2022;14(16):3367.

Oliveira I, Belenichev I, Demchenko A, Bobrova V, Kucherenko L, Gorchakova N, et al. Nootrópicos na terapia comlex de isquemia cerebral crônica. pp. 56–68.

Nicholson CD. Pharmacology of nootropics and metabolically active compounds in relation to their use in dementia. 101, 147–159 (1990).

Cavalcanti V, Marques M, Rocha A, Ferreira IDJ, Leão DP, et al. Bioproducts based on guarana (Paulinia cupana) for practitioners of physical activity. 2020: 8, 1746–1759.

Kennedy D, Haskell C, Wesnes K, Scholey A. Improved cognitive performance in human volunteers following administration of guarana (Paullinia cupana) extract: Comparison and interaction with Panax ginseng. Pharmacol. Biochem. Behav. 2004: 79, 401–411.

Wikoff D, Welsh BT, Henderson R, Brorby GP, Britt J, Myers E. Systematic review of the potential adverse effects of caffeine consumption in healthy adults, pregnant women, adolescents, and children. Food Chem Toxicol. 2017 Nov;109: 585-648.

Echeverri, Darío, et al. "Caffeine's vascular mechanisms of action." International journal of vascular medicine 2010 (2010).

Brunton, Laurence L. et al. Goodman & Gilman: As bases farmacológicas da terapêutica. 11a Edição. Porto Alegre (RS): Mc Graw Hill/Artmed, 2010.

Kolahdouzan M, Hamadeh M. The neuroprotective effects of caffeine in neurodegenerative diseases. CNS Neurosci Ther. 2017 Apr:23(4):272-290.

Kim I, O'Reilly E, Hughes K, Gao X, Schwarzschild M, McCullough M, et al. Interaction between caffeine and polymorphisms of glutamate ionotropic receptor NMDA type subunit 2A (GRIN2A) and cytochrome P450 1A2 (CYP1A2) on Parkinson's disease risk. Mov Disord. 2018: 33(3):414-420

Siokas V, Aloizou A, Tsouris Z, et al. ADORA2A rs5760423 and CYP1A2 rs762551 Polymorphisms as Risk Factors for Parkinson's Disease. J Clin Med. 2021:10(3):381. Published 2021

Popat R, Van Den Eeden S, Tanner C, Kamel F, Umbach D, Marder K, et al (2011), Coffee, ADORA2A, and CYP1A2: the caffeine connection in Parkinson’s disease. European Journal of Neurology, 18: 756-765.

Wang L, Shen X, Wu Y, Zhang D. Coffee and caffeine consumption and depression: A meta-analysis of observational studies. Australian & New Zealand Journal of Psychiatry. 2016;50(3):228-242.

Kim J, Kim J. Green Tea, Coffee, and Caffeine Consumption Are Inversely Associated with Self-Report Lifetime Depression in the Korean Population. Nutrients. 2018: 10(9):1201.

Lucas, Michel, et al. "Coffee, caffeine, and risk of depression among women." Archives of internal medicine 171.17 (2011): 1571-1578.

Perera V, Gross AS, Xu H, McLachlan AJ. Pharmacokinetics of caffeine in plasma and saliva, and the influence of caffeine abstinence on CYP1A2 metrics. J Pharm Pharmacol. 2011 Se:63(9):1161-

Kashuba A, Nafziger A, Kearns G, Leeder J, Gotschall R, Rocci M. Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6, and CYP3A as determined by phenotyping. Clin Pharmacol Ther. 1998 Sep 64(3):257-68